dapoxetine

Ligand id: 7901

Name: dapoxetine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: dapoxetine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 12.47
Molecular weight 305.18
XLogP 7.38
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI), for the treatment of premature ejaculation [4].
This drug is not approved by the US FDA. National approval agencies in countries including Austria, Germany, Argentina, Mexico, New Zealand, Finland, Italy and Portugal have granted marketing authorisation. In the UK dapoxetine hydrochloride, with brand name Priligy, has been available since 2008.
A Phase III clinical trial in the US, NCT00211094, has been completed but approval has still not been granted.
Mechanism Of Action and Pharmacodynamic Effects
Dapoxetine inhibits the serotonin transporter SERT (SLC6A4) [2-3], acting centrally to inhibit the ejaculatory expulsion reflex [1].
External links